The most widely prescribed medication for addiction, almost by default
En los laboratorios y en los registros de salud de veteranos, una pregunta inesperada ha comenzado a tomar forma: ¿podrían los medicamentos que ya combaten la diabetes y la obesidad interrumpir también el ciclo de la adicción? Los fármacos GLP-1, conocidos por marcas como Ozempic y Wegovy, parecen actuar sobre los circuitos de recompensa del cerebro de maneras que podrían reducir el deseo compulsivo de alcohol y otras sustancias. En un país donde más de 79,000 personas murieron por sobredosis en 2024, la posibilidad —aún sin confirmar por ensayos rigurosos— representa tanto una esperanza científica como un recordatorio de la urgencia humana que la impulsa.
- Más de 79,000 muertes por sobredosis en Estados Unidos en 2024 mantienen la presión sobre investigadores y sistemas de salud para encontrar tratamientos nuevos y eficaces.
- Los datos preliminares de registros médicos de veteranos sugieren que quienes toman GLP-1 presentan menores tasas de trastornos por uso de sustancias, pero los estudios observacionales no pueden probar causalidad.
- Los efectos secundarios —náuseas, pancreatitis, daño renal silencioso— exigen monitoreo continuo y plantean interrogantes serios sobre la seguridad a largo plazo en poblaciones vulnerables.
- Ensayos clínicos controlados y aleatorizados están en marcha para determinar si el beneficio observado proviene del medicamento o de características particulares de los pacientes que ya lo tomaban.
- Si los resultados son positivos, estos fármacos podrían convertirse casi automáticamente en la farmacoterapia más prescrita para la adicción, dado que millones de personas ya los usan para otras condiciones.
Los investigadores se preguntan si los medicamentos que ya ocupan los botiquines de millones de personas podrían ayudar a resolver uno de los problemas más persistentes de Estados Unidos: la adicción. Los fármacos GLP-1 —semaglutida, vendida como Ozempic para la diabetes y Wegovy para la obesidad, junto con Mounjaro y Zepbound— fueron diseñados para regular el apetito y el azúcar en sangre. Pero la evidencia emergente sugiere que también podrían amortiguar las vías de recompensa del cerebro, reduciendo el deseo de alcohol y otras drogas.
Estudios preliminares basados en registros de salud de veteranos indican que los pacientes que toman estos medicamentos presentan menores tasas de trastornos por uso de sustancias y menos muertes relacionadas con la adicción. El Dr. W. Kyle Simmons, de la Universidad Estatal de Oklahoma, señala que si estos fármacos resultan seguros y eficaces para tratar la adicción, se convertirían casi por defecto en los más recetados para esa condición, simplemente porque la infraestructura para prescribirlos ya existe.
Sin embargo, la evidencia actual tiene límites importantes. Los hallazgos más prometedores provienen de datos observacionales, no de ensayos controlados diseñados específicamente para tratar la adicción. Las personas que inician terapia con GLP-1 pueden diferir en motivación, salud general y acceso a la atención, factores que podrían distorsionar los resultados. Sin ensayos aleatorizados rigurosos, no es posible saber si el beneficio aparente viene del medicamento o del perfil de quienes lo toman.
Los efectos secundarios son reales: náuseas, vómitos y diarrea son frecuentes al inicio, y existen riesgos más serios relacionados con el páncreas y los riñones. La pancreatitis aparece hasta nueve veces más que con otros medicamentos, y el daño renal puede progresar de forma silenciosa. La deshidratación por síntomas gastrointestinales también preocupa a los expertos.
Con más de 79,000 muertes por sobredosis en 2024, la urgencia de encontrar nuevos tratamientos es innegable. Si los GLP-1 pudieran reducir aunque sea una fracción de esas muertes, la balanza entre riesgos y beneficios cambiaría radicalmente. La pregunta ahora es si la promesa inicial resistirá el escrutinio de la ciencia rigurosa.
Researchers are beginning to ask whether drugs already sitting in millions of medicine cabinets might help solve one of America's most intractable problems: addiction. GLP-1 medications—semaglutida, sold as Ozempic for diabetes and Wegovy for weight loss, along with Mounjaro and Zepbound—were designed to regulate appetite and blood sugar. But emerging evidence suggests they may also dampen the brain's reward pathways in ways that could reduce cravings for alcohol and other drugs.
The drugs work on multiple systems in the body. Beyond their primary effects on digestion and appetite, they have shown promise against heart disease, heart failure, sleep apnea, and kidney disease. Now researchers are investigating whether that same mechanism—the way these medications reshape how the brain processes reward—might interrupt the cycle of addiction itself. Early studies, drawn largely from veteran health records, hint that patients taking GLP-1 drugs show lower rates of substance use disorders and fewer addiction-related deaths. As clinical trials expand, researchers expect more definitive answers about alcohol use disorder in particular.
The potential is striking enough that experts are already imagining the implications. Dr. W. Kyle Simmons, a pharmacology and physiology professor at Oklahoma State University, has suggested that if these drugs prove both safe and effective for addiction treatment, they would likely become the most widely prescribed medication for the condition almost by default—simply because so many people are already taking them for other reasons. The infrastructure for prescribing, monitoring, and distributing them already exists.
But the current evidence comes with important caveats. The most promising findings rely on observational data—looking at what happened to people who were already taking these drugs for diabetes or weight loss, rather than testing them in controlled trials specifically designed to treat addiction. Researchers caution that the people who start GLP-1 therapy may differ in important ways from the broader population struggling with substance use. Their motivation to change, their overall health, their access to care—all these factors could skew the results. To know whether the drugs actually work for addiction, rigorous randomized controlled trials are essential. Without them, it remains unclear whether the apparent benefit comes from the medication itself or from the characteristics of the patients taking it.
The side effects are real and sometimes serious. Nausea, vomiting, and diarrhea are common, especially early on, though they often fade with time. More concerning are the risks to the pancreas and kidneys. GLP-1 drugs are associated with pancreatitis at rates up to nine times higher than other medications, and they can damage kidney function in ways that progress silently—meaning patients need continuous monitoring. There are also questions about cardiovascular safety, though some studies suggest net benefits in certain populations. Dehydration from gastrointestinal side effects is another concern, and the World Health Organization has flagged frequent digestive symptoms as a widespread issue.
Yet the stakes for finding new treatments are enormous. In 2024, drug overdose deaths in the United States exceeded 79,000, according to the Centers for Disease Control and Prevention. That number represents not just a medical crisis but a public health emergency that has resisted conventional interventions. If GLP-1 drugs could reduce even a fraction of those deaths, the calculus around their risks and benefits would shift dramatically. The question now is whether the early promise will hold up under the scrutiny of rigorous science—and whether the medical system can move quickly enough to find out.
Citas Notables
If these drugs prove safe and effective for substance use disorders, they would likely become the most widely prescribed medication for addiction given their existing widespread use in society— Dr. W. Kyle Simmons, Oklahoma State University
La Conversación del Hearth Otra perspectiva de la historia
Why are researchers suddenly interested in diabetes drugs for addiction?
The mechanism is the key. These medications reshape how the brain processes reward and appetite. That same rewiring appears to quiet the craving signals that drive addiction, at least based on what we're seeing in the data.
But you said the evidence is observational. What does that actually mean?
It means we're looking backward at people who were already taking these drugs for other reasons. We're not running experiments where we give some people the drug and others a placebo to see what happens. That's the difference between noticing a pattern and proving cause and effect.
If they work, why aren't they already being prescribed for addiction?
Because we don't know yet if they actually work for this specific purpose. The early signals are encouraging, but they could be misleading. The people taking these drugs might be more motivated to change, or healthier overall, or have better access to support. We need controlled trials to separate the drug's effect from everything else.
What worries you most about these medications?
The pancreas and kidney risks are serious. Pancreatitis can be life-threatening, and kidney damage can happen quietly, without symptoms, until it's advanced. If we're going to use these drugs for addiction—a chronic condition requiring long-term treatment—we need to understand those long-term safety profiles much better than we do now.
Given that 79,000 people died from overdoses last year, shouldn't we be moving faster?
That's the tension. The death toll is real and urgent. But rushing an unproven treatment into widespread use could create new harms. The answer is probably to run the trials as quickly as possible while being rigorous about what we're measuring and how we're measuring it.